The Pakistan Single Window (PSW), in collaboration with the Drug Regulatory Authority of Pakistan (DRAP), has introduced a new digital system to enhance the export competitiveness of Pakistan’s pharmaceutical sector. This initiative includes the launch of the Digital Certificate of Pharmaceutical Product (COPP), a key requirement for pharmaceutical exports to international markets.
In addition to the COPP, the DRAP Clearance Gateway now offers a range of electronic certificates, including the Free Sale Certificate, Good Manufacturing Practice (GMP) Certificate, and No Objection Certificate (NOC) for exports. These certificates aim to streamline the regulatory process, reduce delays, and ensure compliance with global standards.
All certificates issued through the PSW platform are digitally secure, verifiable, and contain a unique QR code for instant authentication. This move eliminates inefficiencies associated with paper documentation and improves compliance with international regulations, particularly in high-demand markets such as the European Union and the United States.
Aftab Haider, CEO of PSW, expressed enthusiasm about the initiative, stating, “The Digital COPP aligns Pakistan’s pharmaceutical industry with global best practices, improving regulatory efficiency and boosting exports by ensuring our products meet international standards.” He added that the initiative is part of the Prime Minister’s vision for a Digital Pakistan.
Dr. Obaidullah Malik, CEO of DRAP, emphasized that the new digital certificates reflect Pakistan’s commitment to modernizing regulatory practices and fostering greater global trust in its pharmaceutical sector.
In the fiscal year 2023-24, Pakistan’s pharmaceutical exports reached approximately $341 million, marking a 3.9% increase from the previous year. This initiative is part of a broader strategy to digitalize regulatory systems, enhance operational efficiency, and drive export-led growth in the pharmaceutical sector.
